EUVIMEDEUVIMED entdecken
Crossref

Artificial Intelligence Assisted Drug Discovery and Clinical Development for Accelerating Therapeutic Innovation

Devendra Kumar Sahu

Biotechnology Frontiers · 13.03.2026 · 6 (1) · 32-40

DOI: 10.51470/bf.2026.6.1.32 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology Frontiers, online erschienen am 09.04.2026. Verfasst von Devendra Kumar Sahu.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pharmaceutical industry faces significant challenges in drug discovery and clinical development, including high costs, lengthy timelines, and low success rates. Artificial intelligence (AI) has emerged as a transformative technology capable of revolutionizing various stages of the drug development pipeline. The leveraging machine learning, deep learning, natural language processing, and advanced data analytics, AI facilitates rapid identification of drug targets, prediction of molecular properties, optimization of lead compounds, and enhancement of clinical trial design. AI-driven approaches enable researchers to analyze large-scale biological, chemical, genomic, and clinical datasets, thereby improving decision-making and reducing the risks associated with traditional drug development processes. Recent advances in computational modeling and generative AI have accelerated the discovery of novel therapeutic candidates and expanded opportunities for drug repurposing. Furthermore, AI contributes to personalized medicine through patient stratification, biomarker identification, and prediction of treatment responses. Despite these advantages, challenges related to data quality, model interpretability, regulatory compliance, ethical concerns, and cybersecurity remain significant barriers to widespread implementation. This review examines the current applications of AI across drug discovery and clinical development, highlights recent technological advancements, discusses major challenges and regulatory considerations, and explores future directions for integrating AI into pharmaceutical innovation. The findings suggest that AI has the potential to significantly enhance efficiency, reduce development costs, and accelerate the delivery of safe and effective therapies to patients worldwide.

Zitieren

APA

Sahu, D. K. (2026). Artificial Intelligence Assisted Drug Discovery and Clinical Development for Accelerating Therapeutic Innovation. Biotechnology Frontiers, 6(1), 32-40. https://doi.org/10.51470/bf.2026.6.1.32

Vancouver

Sahu DK. Artificial Intelligence Assisted Drug Discovery and Clinical Development for Accelerating Therapeutic Innovation. Biotechnology Frontiers. 2026;6(1):32-40. doi:10.51470/bf.2026.6.1.32

BibTeX
@article{Sahu2026,
  author = {Sahu, Devendra Kumar},
  title = {Artificial Intelligence Assisted Drug Discovery and Clinical Development for Accelerating Therapeutic Innovation},
  journal = {Biotechnology Frontiers},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {32--40},
  doi = {10.51470/bf.2026.6.1.32}
}
Kostenlos starten →